Skip navigation
Premark Pharma
Menu
  • Home
  • People
    • Management & Advisors
    • Board of Directors
    • Investors
  • Projects
    • Blepharitis – Phase 3
    • What is Blepharitis?
    • Dry Eye / Ocular Surface Inflammation – Phase 3
  • News
  • Contact

News

Latest News

May 2024

Phase 2b Clinical Data on Treatment of Dry Eye, Presented at ARVO Annual Meeting

December 2021

Partnering Deal Agreed for Development & Commercialisation of PMP2207

June 2019

Exclusive Worldwide License Acquired from Novartis Pharma AG

March 2019

Premark successfully closes fully subscribed seed finance round

April 2018

Premark Pharma GmbH incorporated in Switzerland

© Premark Pharma GmbH 2018 - 2025

Company registered in Switzerland CHE-473.607.447
Registered Office:
Christoph Merian-Ring 11, 4153 Reinach, Switzerland

Web Design by Smooth Pixel